GenSight Biologics is a technology company.
GenSight Biologics has raised $78.0M across 2 funding rounds.
GenSight Biologics has raised $78.0M in total across 2 funding rounds.
GenSight Biologics has raised $78.0M in total across 2 funding rounds.
GenSight Biologics's investors include Abingworth, HealthCap, Versant Ventures.
GenSight Biologics S.A. is a clinical-stage biopharmaceutical company developing gene therapies for retinal neurodegenerative diseases and central nervous system disorders, primarily targeting irreversible blindness in conditions like Leber Hereditary Optic Neuropathy (LHON).[1][3][4] Its lead product, LUMEVOQ (GS010 or lenadogene nolparvovec), is an AAV2-based gene therapy in late-stage Phase III trials for LHON caused by ND4 mutations, administered via single intravitreal injection to restore mitochondrial function and vision.[1][2][5][6] The company serves patients with rare sight-threatening diseases, solving unmet needs in vision preservation through proprietary Mitochondrial Targeting Sequence (MTS) and optogenetics platforms; its second candidate, GS030, combines gene therapy with biomimetic goggles for retinitis pigmentosa (RP) and dry age-related macular degeneration (AMD), currently in Phase I/II trials.[3][5][6] Backed by specialist investors like Sofinnova Partners, GenSight shows growth momentum with completed Phase III trials for LUMEVOQ, regulatory progress including EMA validation of its Marketing Authorisation Application, and preclinical programs expanding into other ophthalmic and neurodegenerative areas.[2][6]
GenSight Biologics emerged from pioneering research in gene therapy for mitochondrial and retinal diseases, leveraging licenses from leading institutions like Sorbonne Université, CNRS, Inserm, Genethon, Harvard, MIT, and Novartis.[1] Founded as a Paris-based biotech (with a New York office), it went public via IPO on Euronext, specializing in therapies for mitochondrial diseases and eye neurodegeneratives.[3][8][10] The company's idea stemmed from applying MTS technology—which shuttles nuclear-encoded genes to mitochondria—and optogenetics to address blinding conditions without existing cures, starting with LHON affecting teens and young adults.[2][4][5] Early traction included advancing GS010 to Phase III and securing a solid investor base of healthcare specialists, including Sofinnova Partners as a founding and lead investor in its crossover strategy.[2][6] Pivotal moments feature strong clinical data from three completed Phase III trials for LUMEVOQ, remediation of manufacturing issues, and ongoing PIONEER Phase I/II for GS030 showing efficacy signals.[6]
GenSight rides the gene therapy wave in ophthalmology, targeting rare neurodegenerative retinal diseases amid surging demand for one-time cures in a market projected to grow with aging populations and rising blindness prevalence (e.g., RP, AMD, LHON).[3][4][6] Timing aligns with regulatory advances—like EMA's MAA validation for LUMEVOQ—and maturing AAV vectors/optogenetics, enabling breakthroughs in mutation-specific (MTS) and agnostic therapies.[2][6] Favorable forces include resolved CMC challenges, strong natural history contrasts in trials, and partnerships accelerating from bench to clinic.[1][6] The company influences the ecosystem by validating intravitreal gene delivery for CNS disorders, inspiring mutation-agnostic optogenetics, and contributing to global leadership via investor networks like Sofinnova's medtech/biopharma focus.[2]
GenSight is poised for commercialization with LUMEVOQ's new Phase III launch in Q2 2024 and fresh European regulatory submission, potentially marking its first approval in LHON.[6] GS030's Phase I/II efficacy could expand to broader photoreceptor losses, while preclinical assets target additional indications.[6][7] Trends like optogenetics maturation, AAV improvements, and CNS expansion will shape its path, evolving GenSight from clinical biotech to multi-product leader transforming blindness treatment—fulfilling its mission to deliver long-lasting vision restoration where none existed.[4][6]
GenSight Biologics has raised $78.0M across 2 funding rounds. Most recently, it raised $36.0M Series B in July 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2015 | $36.0M Series B | Abingworth, HealthCap | |
| Apr 1, 2013 | $42.0M Series A | Abingworth, HealthCap, Versant Ventures |